Your shopping cart is empty

Subscriber login

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Merck’s Potential Insomnia Treatment Proves Effective in Phase III Trials

Drug Industry Daily

June 14, 2012 | Vol. 11 No. 117

Merck’s Potential Insomnia Treatment Proves Effective in Phase III Trials

Results from two Phase III trials for Merck’s insomnia drug suvorexant show it met all but one of its primary endpoints, setting Merck up for an NDA filing this year.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Lilly Phase III Non-Hodgkin’s Lymphoma Drug Trial Halted Boehringer Ingelheim’s NSCLC Candidates Get Mixed Results Rise in Global Trial Recruitment Raises Ethics, Compliance Concerns in EU Lilly Halts Phase III Trial of Non-Hodgkin’s Lymphoma Candidate

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.